161 related articles for article (PubMed ID: 35806301)
1. Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer.
Gardner KP; Cristofanilli M; Chumsri S; Lapidus R; Tang CM; Raghavakaimal A; Adams DL
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806301
[TBL] [Abstract][Full Text] [Related]
2. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
[TBL] [Abstract][Full Text] [Related]
3. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
Mu Z; Benali-Furet N; Uzan G; Znaty A; Ye Z; Paolillo C; Wang C; Austin L; Rossi G; Fortina P; Yang H; Cristofanilli M
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27706044
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Profiling of Cancer-Associated Cells in the Blood of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy to Predict Pathological Complete Response.
Pore AA; Dhanasekara CS; Navaid HB; Vanapalli SA; Rahman RL
Bioengineering (Basel); 2023 Apr; 10(4):. PubMed ID: 37106672
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 expression in tumor associated cells in blood is prognostic for progression and survival in pancreatic cancer.
Gardner KP; Tsai S; Aldakkak M; Gironda S; Adams DL
PLoS One; 2022; 17(3):e0264763. PubMed ID: 35259193
[TBL] [Abstract][Full Text] [Related]
6. Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab.
Augustyn A; Adams DL; He J; Qiao Y; Verma V; Liao Z; Tang CM; Heymach JV; Tsao AS; Lin SH
Clin Lung Cancer; 2021 May; 22(3):e451-e465. PubMed ID: 32798130
[TBL] [Abstract][Full Text] [Related]
7. Identification and Morphological Characterization of Features of Circulating Cancer-Associated Macrophage-like Cells (CAMLs) in Endometrial Cancers.
Sulaiman R; De P; Aske JC; Lin X; Dale A; Vaselaar E; Ageton C; Gaster K; Espaillat LR; Starks D; Dey N
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230499
[TBL] [Abstract][Full Text] [Related]
8. Cytopathological Heterogeneity of Circulating Tumor Cells in Non-metastatic Esophageal Adenocarcinoma.
Kuvendjiska J; Pitman MB; Martini V; Braun C; Grebe K; Timme S; Fichtner-Feigl S; Glatz T; Schmoor C; Guenzle J; Hoeppner J; Kulemann B
Anticancer Res; 2020 Oct; 40(10):5679-5685. PubMed ID: 32988893
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer.
Cierna Z; Mego M; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Cingelova S; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2014 Jun; 14():472. PubMed ID: 24972610
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.
Papadaki MA; Kallergi G; Zafeiriou Z; Manouras L; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
BMC Cancer; 2014 Sep; 14():651. PubMed ID: 25182808
[TBL] [Abstract][Full Text] [Related]
12. LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells.
Trapp EK; Majunke L; Zill B; Sommer H; Andergassen U; Koch J; Harbeck N; Mahner S; Friedl TWP; Janni W; Rack B; Alunni-Fabbroni M
Mol Oncol; 2017 Nov; 11(11):1508-1526. PubMed ID: 28700115
[TBL] [Abstract][Full Text] [Related]
13. Beta 2 adrenergic receptor and mu opioid receptor interact to potentiate the aggressiveness of human breast cancer cell by activating the glycogen synthase kinase 3 signaling.
Rousseau B; Murugan S; Palagani A; Sarkar DK
Breast Cancer Res; 2022 May; 24(1):33. PubMed ID: 35568869
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal-Epithelial Transition and Circulating Tumor Cells in Small Cell Lung Cancer.
Hamilton G; Rath B
Adv Exp Med Biol; 2017; 994():229-245. PubMed ID: 28560677
[TBL] [Abstract][Full Text] [Related]
15. Clinical Relevancy of Circulating Tumor Cells in Breast Cancer: Epithelial or Mesenchymal Characteristics, Single Cells or Clusters?
Fridrichova I; Kalinkova L; Ciernikova S
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292996
[TBL] [Abstract][Full Text] [Related]
16. Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy.
Adams DL; Adams DK; He J; Kalhor N; Zhang M; Xu T; Gao H; Reuben JM; Qiao Y; Komaki R; Liao Z; Edelman MJ; Tang CM; Lin SH
Clin Cancer Res; 2017 Oct; 23(19):5948-5958. PubMed ID: 28679765
[No Abstract] [Full Text] [Related]
17. Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer.
Ueo H; Sugimachi K; Gorges TM; Bartkowiak K; Yokobori T; Müller V; Shinden Y; Ueda M; Ueo H; Mori M; Kuwano H; Maehara Y; Ohno S; Pantel K; Mimori K
Br J Cancer; 2015 Apr; 112(9):1519-26. PubMed ID: 25880010
[TBL] [Abstract][Full Text] [Related]
18. Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients.
Krawczyk N; Meier-Stiegen F; Banys M; Neubauer H; Ruckhaeberle E; Fehm T
Biomed Res Int; 2014; 2014():415721. PubMed ID: 24895575
[TBL] [Abstract][Full Text] [Related]
19. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
[TBL] [Abstract][Full Text] [Related]
20. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
